Cancer Discovery

Novel drug delivery platform efficiently delivers antibodies across the Blood-Brain Barrrier at therapeutic doses

A biopharmaceutical company, Bioasis Technologies, developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical-need, including brain cancers and neurodegenerative diseases, announced the publication of independent research validating the ability of the company’s xB3 platform to […]